within Pharmacolibrary.Drugs.ATC.D;

model D01AE21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 4.1666666666666665e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01155,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D01AE21</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Flucytosine is an antifungal medication used primarily for the treatment of serious fungal infections, such as cryptococcal meningitis and systemic candidiasis, often in combination with other agents like amphotericin B. It is still in clinical use for these indications.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetics in adult patients with normal renal function; reported parameters are from multiple clinical studies of oral administration.</p><h4>References</h4><ol><li><p>Fisher, JF, et al., &amp; Newman, CA (2011). Candida urinary tract infections--treatment. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 52 Suppl 6 S457–S466. DOI:<a href=\"https://doi.org/10.1093/cid/cir112\">10.1093/cid/cir112</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21498839/\">https://pubmed.ncbi.nlm.nih.gov/21498839</a></p></li><li><p>Béguin, J, et al., &amp; Maurey, C (2021). Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs. <i>BMC veterinary research</i> 17(1) 220–None. DOI:<a href=\"https://doi.org/10.1186/s12917-021-02927-5\">10.1186/s12917-021-02927-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34154593/\">https://pubmed.ncbi.nlm.nih.gov/34154593</a></p></li><li><p>Pai, MP, et al., &amp; Felton, LA (2010). Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine. <i>Antimicrobial agents and chemotherapy</i> 54(3) 1237–1241. DOI:<a href=\"https://doi.org/10.1128/AAC.01103-09\">10.1128/AAC.01103-09</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20038612/\">https://pubmed.ncbi.nlm.nih.gov/20038612</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D01AE21;
